Transforming Testing & Treatment Together
Giving you confidence in the performance of our systems and assays in your laboratory
Our commitment to quality
As pioneers of polymerase chain reaction (PCR) technology, we continue to demonstrate our commitment to scientific and clinical excellence. Roche systems and assays are the trusted choice in clinical trials across the industry—from plasma and blood screening and viral load testing to more recent leadership with HPV Primary Screening and advances in oncology testing with the cobas® EGFR Mutation Test v2. We hold our products to the highest performance standards to give you confidence in every result.
Advanced assay design
Our unrivaled investment in research and development allows us to stay ahead of constantly evolving diseases, lets you inform the best possible treatment decisions, and ensures we can keep the blood supply safe for all. Through an unrelenting dedication to innovation, Roche consistently delivers industry leading breakthroughs:
Ensuring confidence in results
Results generated on Roche systems are proven to be standardised and comparable across all platforms.1* The performance of new assays is verified with high precision across platforms for accuracy and traceability according to World Health Organization (WHO) standards.
Personalised solutions for your specific needs Working closely with our partners helps to strengthen our relationship and understanding of what solutions you need today and may need in the future.
Comprehensive solutions to meet your molecular testing needs
Our broad assay menu offers solutions for any throughput or molecular testing
Our diverse offering of nucleic acid purification and qPCR solutions enable you to expand,
customise, and standardise your lab's LDT portfolio.
Automation & IT in Molecular Diagnostic Testing
Experience a new paradigm in workflow efficiency. Roche pre- and post-analytic solutions enable personalised laboratory automation with cross-disciplinary connectivity.
Workflow and technical consulting
Our experts are specialised, local, and at your service to help you optimise your workflow and processes with the right technology for your future laboratory needs. Based on your key performance criteria—financial, clinical, quality or personnel—we can work with you to improve turnaround time (TAT), reduce errors, and create a more efficient use of your space and manpower.Contact
Premium service & support
Our team of national, regional, and international application specialists are there when you need them, providing timely technical advice to help you get the most out of your tests and systems. In situations where your equipment might require support, we have a large on-the-ground force to ensure nothing gets in the way of your testing. Roche has more engineers and service personnel than any other diagnostic provider, so you don't have to wait for days until you get the help you need.Contact
Invest in innovation
When you choose a solution from Roche, you're securing your future. We invest heavily into molecular diagnostics—in new assays, instruments (systems), and enhancements and through internal developments and external acquisitions. We stand behind every product and service, and want to ensure the solution that you choose delivers a top-quality experience and fosters a long-term partnership.
Our commitment to excellence, corporate stability, and delivery of innovation makes Roche the ideal choice for the future of your lab. You can be confident that our products and applications will continue to be supported into the future, and that we will adapt as your needs change.
- Performance evaluation of the new real-time PCR-based COBAS® HCV assay for use on the COBAS 6800/8800 systems for the detection and quantification of HCV RNA - RING Study. Poster presented at AASLD, Nov 11-14, 2016, Boston, MA, USA.
- Iordanoaia N, et al. Cross-contamination compliance of cobas p 612 pre-analytical system in use with cobas® 6800/8800 Systems. Declaration of Serology and NAT testing compliance. Poster presented at ISBT, Dubai, UAE, 2016 September.